((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST

Depressive Disorder, Major

Janssen Research & Development, LLCSmall moleculePhase 3Active

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 65/ 100
Competitive Position: 81/ 100

Competitive context

234 Active assets in the Depressive Disorder, Major cohort.

Asset / Sponsor	Phase	Rating
Risperdal Johns Hopkins University	Phase 4	BBB
Zelapar Corium Innovations, Inc.	Phase 4	BBB
EDIVOXETINE Eli Lilly and Company	Phase 3	BBB
S-Ketamine Janssen Research & Development, LLC	Phase 4	BBB
Opc-34712 Nova Scotia Health Authority	Phase 4	BBB

View all 50 →

Same molecule, other indications

((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST is also rated in:

Alzheimer diseaseDormant

CCC

Indicative ·

51 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →